Sirna kakuu galuu Pirezidaant Tiraamp Wiixata darbe gaggeeffame irratti paastaroonni Afrikaa lama argamanii turan.
The oversubscribed Series B will boost the clinical development of two RNAi therapies for epilepsy and Huntington’s disease ...
Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small ...
Meerkuriin pilaanetota biroo jaha kan duraanuu mul'taa jiranitti makamuun pilaanetota torba tarree galanii arguuf jirra jedhu ...
New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating ...
Silexion Therapeutics Corp. (NASDAQ:SLXN) released new preclinical data for SIL-204, its next-generation siRNA therapeutic ...
The company, co-founded by Nobel Laureate Craig Mello, aims to push molecules for Huntington’s and a form of epilepsy into ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
H.C. Wainwright analyst Patrick Trucchio reiterates a Buy rating and $75 price target on Silence Therapeutics (SLN) shares following a recent ...
Four top athlete alumni at Independence High School are to be honored by being inducted into the school’s Hall of Fame.
Atalanta Therapeutics is building on the growing attention around RNAi-based medicines with its $97 million Series B financing and plans to enter the clinic.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback